



**SCIENCE: 19-21 SEPTEMBER 2020**  
**EDUCATION: 16-18 OCTOBER 2020**

## Presidential Symposium I

Date 19.09.2020

Time 18:30 - 20:10

Room Channel 1

Chairs Solange Peters (Lausanne, Switzerland), John B. Haanen (Amsterdam, Netherlands)

### Q Proffered Paper session



LBA1 - Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): central nervous system (CNS) disease recurrence

Presentation Number LBA1

Lecture Time 18:30 - 18:42

Speakers Masahiro Tsuboi (Kashiwa, Chiba, Japan)

## Osimertinib adjuvant therapy in patients with resected EGFR mutated NSCLC (ADAURA): CNS disease recurrence

**Masahiro Tsuboi**,<sup>1</sup> **Yi-Long Wu**,<sup>2</sup> **Jie He**,<sup>3</sup> **Thomas John**,<sup>4</sup> **Christian Grohe**,<sup>5</sup> **Margarita Majem**,<sup>6</sup> **Jonathan W Goldman**,<sup>7</sup> **Konstantin Laktionov**,<sup>8</sup> **Sang-We Kim**,<sup>9</sup> **Terufumi Kato**,<sup>10</sup> **Huu Vinh Vu**,<sup>11</sup> **Charuwan Akewanlop**,<sup>12</sup> **Chong-Jen Yu**,<sup>13</sup> **Filippo de Marinis**,<sup>14</sup> **Manuel Domine**,<sup>15</sup> **Frances A Shepherd**,<sup>16</sup> **Chris Yan**,<sup>17</sup> **Ajlan Atasoy**,<sup>18</sup> **Roy S. Herbst**<sup>19</sup>

<sup>1</sup>Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan; <sup>2</sup>Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China; <sup>3</sup>Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; <sup>4</sup>Department of Medical Oncology, Austin Health, Melbourne, Australia; <sup>5</sup>Department of Respiratory Diseases, Evangelische Lungenklinik, Berlin, Germany; <sup>6</sup>Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; <sup>7</sup>David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA; <sup>8</sup>Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russia; <sup>9</sup>Department of Oncology, Asan Medical Center, Seoul, South Korea; <sup>10</sup>Department of Thoracic Oncology, Kanagawa Cancer Center, Asahi Ward, Yokohama, Japan; <sup>11</sup>Department Thoracic Surgery, Choray Hospital, Ho Chi Minh City, Vietnam; <sup>12</sup>Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; <sup>13</sup>Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan; <sup>14</sup>Thoracic Oncology Division, European Institute of Oncology (IEO), IRCCS, Milan, Italy; <sup>15</sup>Instituto de Investigación Sanitaria-Fundación de la Jimenez Diaz (IIS-FJD), Milan, Spain; <sup>16</sup>Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; <sup>17</sup>Late Oncology Statistics, AstraZeneca, Cambridge, UK; <sup>18</sup>Oncology Research & Development, AstraZeneca, Cambridge, United Kingdom; <sup>19</sup>Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA



## LBA2 - Lorlatinib vs Crizotinib in the First-line Treatment of Patients (pts) with Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC): Results of the Phase 3 CROWN Study

Presentation Number LBA2

Lecture Time 19:02 - 19:14

Speakers Benjamin Solomon (Melbourne, VIC, Australia)



### Lorlatinib vs Crizotinib in the First-line Treatment of Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Results of the Phase 3 CROWN Study

Solomon B,<sup>1</sup> Bauer T,<sup>2</sup> de Marinis F,<sup>3</sup> Felip E,<sup>4</sup> Goto Y,<sup>5</sup> Liu G,<sup>6</sup> Mazieres J,<sup>7</sup> Kim D-W,<sup>8</sup> Mok T,<sup>9</sup> Polli A,<sup>10</sup> Thurm H,<sup>11</sup> Calella AM,<sup>10</sup> Peltz G,<sup>12</sup> Shaw A<sup>13</sup>

<sup>1</sup>Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; <sup>2</sup>Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, USA; <sup>3</sup>European Institute of Oncology, IRCCS, Milan, Italy; <sup>4</sup>Vall d'Hebron University Hospital, Barcelona, Spain; <sup>5</sup>National Cancer Center Hospital, Tokyo, Japan; <sup>6</sup>University Health Network, Toronto, Canada; <sup>7</sup>Claudius Regaud Institute, Toulouse, France; <sup>8</sup>Seoul National University Hospital, Seoul, South Korea; <sup>9</sup>State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong; <sup>10</sup>Pfizer Inc., Milan, Italy; <sup>11</sup>Pfizer Inc., La Jolla, CA, USA; <sup>12</sup>Pfizer Inc., Boston, MA, USA; <sup>13</sup>Massachusetts General Hospital Cancer Center, Boston, MA, USA

